Abstract
The dynamics of chromatin structure contribute to the regulation of gene transcription and in part, the changes in chromatin structure associated with gene activation/repression are a function of the state of histone acetylation. Histone deacetylases (HDACs) deacetylate histone tails leading to a more compact structure of chromatin that in turn represses gene transcription. Given the rapid activation and/or repression of gene networks following microbial infection, the role of HDACs in the epigenetic regulation of genes involved in the innate and adaptive immune responses has become an area of extensive research. In relation to the immune-modulatory properties of HDAC inhibitors, we provide in the following methodological article an extended description of two techniques—a high throughput qPCR assay combined with PhosFlow cytometry—to evaluate the modulation of antiviral and inflammatory signaling cascades following HDAC inhibitor treatment. The high-throughput qPCR assay is based on the nanofluidic Fluidigm BioMark system that permits the analysis of up to 9216 qPCR reactions at once in a self-design open array chip. Together with the more refined analysis provided with the Phosflow technique, these two strategies offer invaluable tools to measure modulation of innate immune gene networks.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13:673–691
Ellis L, Atadja PW, Johnstone RW (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8:1409–1420
Ropero S, Ballestar E, Alaminos M, Arango D, Schwartz S Jr, Esteller M (2008) Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 27:4008–4012
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953–959
Licciardi PV, Ververis K, Tang ML, El-Osta A, Karagiannis TC (2013) Immunomodulatory effects of histone deacetylase inhibitors. Curr Mol Med 13:640–647
Hassig CA, Tong JK, Fleischer TC, Owa T, Grable PG, Ayer DE, Schreiber SL (1998) A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci U S A 95:3519–3524
Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T, Gatza E, Mascagni P, Dinarello CA, Reddy P (2009) Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 182:5899–5903
Placek K, Coffre M, Maiella S, Bianchi E, Rogge L (2009) Genetic and epigenetic networks controlling T helper 1 cell differentiation. Immunology 127:155–162
West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124:30–39
Nguyen TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, Vanderhyden BC, Werier J, Atkins H, Vaha-Koskela MJ, Stojdl DF, Bell JC, Hiscott J (2008) Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A 105:14981–14986
Shulak L, Beljanski V, Chiang C, Dutta SM, Van Grevenynghe J, Belgnaoui SM, Nguyen TL, Di Lenardo T, Semmes OJ, Lin R, Hiscott J (2014) Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-kappaB-dependent autophagy. J Virol 88:2927–2940
Chiang C, Beljanski V, Yin K, Olagnier D, Ben Yebdri F, Steel C, Goulet ML, DeFilippis VR, Streblow DN, Haddad EK, Trautmann L, Ross T, Lin R, Hiscott J (2015) Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J Virol 89:8011–8025
Olagnier D, Peri S, Steel C, van Montfoort N, Chiang C, Beljanski V, Slifker M, He Z, Nichols CN, Lin R, Balachandran S, Hiscott J (2014) Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells. PLoS Pathog 10:e1004566
Olagnier D, Scholte FE, Chiang C, Albulescu IC, Nichols C, He Z, Lin R, Snijder EJ, van Hemert MJ, Hiscott J (2014) Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. J Virol 88:4180–4194
Olagnier D, Sze A, Bel Hadj S, Chiang C, Steel C, Han X, Routy JP, Lin R, Hiscott J, van Grevenynghe J (2014) HTLV-1 Tax-mediated inhibition of FOXO3a activity is critical for the persistence of terminally differentiated CD4+ T cells. PLoS Pathog 10:e1004575
Acknowledgement
This research was supported by grants from the National Institutes of Health (AI108861 and 1R21CA192185-01 to JH).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Olagnier, D., Chiang, C., Hiscott, J. (2017). Evaluation of Innate Immune Gene Expression Following HDAC Inhibitor Treatment by High Throughput qPCR and PhosFlow Cytometry. In: Krämer, O. (eds) HDAC/HAT Function Assessment and Inhibitor Development. Methods in Molecular Biology, vol 1510. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6527-4_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6527-4_18
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6525-0
Online ISBN: 978-1-4939-6527-4
eBook Packages: Springer Protocols